• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Mid-Afternoon Market Update: Dow Turns Negative; Turquoise Hill Resources Shares Spike Higher

    3/14/22 2:34:39 PM ET
    $BNTX
    $DB
    $KC
    $NKTR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Banks
    Finance
    Get the next $BNTX alert in real time by email

    U.S. stocks turned lower toward the end of trading on Monday as the Dow Jones dropped 100 points, after surging more than 400 points earlier during the session.

    The Dow traded down 0.35% to 32,828.57 while the NASDAQ fell 2.10% to 12,574.22. The S&P also fell, dropping, 0.96% to 4,163.91.

    Also check this: Executives Buy More Than $1.5B Of 3 Stocks


    Leading and Lagging Sectors


    Financials shares climbed by 1.8% on Monday. Meanwhile, top gainers in the sector included Deutsche Bank Aktiengesellschaft (NYSE:DB), up 10% and Sculptor Capital Management, Inc. (NYSE:SCU) up 8%.


    In trading on Monday, energy shares fell by 2.8%.


    Top Headline


    Russia sought China's military equipment to support its invasion of Ukraine, Financial Times reported citing U.S. officials. The U.S. looks to caution its allies against China's possible assistance to Russia.


    Equities Trading UP


    Volt Information Sciences, Inc. (NYSE:VOLT) shares shot up 96% to $5.91 after the company announced it would be acquired for $6 per share.


    Shares of Turquoise Hill Resources Ltd. (NYSE:TRQ) got a boost, shooting 32% to $26.57 after Rio Tinto proposed to acquire the company at C$34 per share.


    BioNTech SE (NASDAQ:BNTX) shares were also up, gaining 12% to $ 152.05. The Pfizer- BioNTech vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15. According to a study conducted by the Centers for Disease Control and Prevention (CDC) and Abt Associates, the shot showed 59% efficacy in those ages 12 to 15 and 31% in those ages 5 to 11.

     


    Equities Trading DOWN

    Nektar Therapeutics (NASDAQ:NKTR) shares tumbled 61% to $4.1599 after the company's Phase 3 PIVOT trial did not meet its primary endpoint.


    Shares of Kingsoft Cloud Holdings Limited (NASDAQ:KC) were down 47% to $2.5950. JP Morgan downgraded Kingsoft Cloud from Neutral to Underweight and announced a $3.5 price target.


    Waitr Holdings Inc. (NASDAQ:WTRH) was down, falling 32% to $0.31 after the company on Friday reported Q4 earnings, posting a year-over-year decline in revenue.


    Also check out: Alphabet And 4 Other Stocks Sold By Insiders


    Commodities

    In commodity news, oil traded down 6.3% to $102.49, while gold traded down 1.3% to $1,959.20.


    Silver traded down 2.9% Monday to $25.405 while copper fell 2.2% to $4.5260.



    Euro zone

    European shares were higher today. The eurozone’s STOXX 600 rose 1.20%, London’s FTSE 100 rose 0.57%, while Spain’s IBEX 35 Index rose 1.13%. The German DAX gained 2.21%, French CAC 40 gained 1.75% and Italy’s FTSE MIB Index gained 1.67%.

    French current account deficit declined to EUR 1.79 billion in January from EUR 7.04 billion in the prior month, while trade deficit shrank to EUR 8.03 billion from EUR 11.39 billion. Wholesale price inflation in Germany increased 16.6% year-over-year in February.


    Economics


    There were no major US economic releases Monday.

    Check out this: 4 Penny Stocks Insiders Are Buying

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 81,174,670 cases with around 993,810 deaths. India confirmed a total of at least 42,993,490 cases and 515,900 deaths, while Brazil reported over 29,368,770 COVID-19 cases with 655,130 deaths. In total, there were at least 458,633,270 cases of COVID-19 worldwide with more than 6,066,830 deaths.

    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $DB
    $KC
    $NKTR

    CompanyDatePrice TargetRatingAnalyst
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Nektar Therapeutics
    $NKTR
    2/10/2026Mkt Perform → Outperform
    William Blair
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Nektar Therapeutics
    $NKTR
    11/26/2025$102.00Buy
    Citigroup
    Kingsoft Cloud Holdings Limited
    $KC
    9/16/2025$21.00Buy
    Deutsche Bank
    Kingsoft Cloud Holdings Limited
    $KC
    9/9/2025Neutral → Buy
    BofA Securities
    Deutsche Bank AG
    $DB
    8/27/2025Buy → Neutral
    Goldman
    More analyst ratings

    $BNTX
    $DB
    $KC
    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN FRANCISCO, March 6, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced that, on February 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 4,300 shares of its common stock to three newly-hired employees under Nektar's 2025 Inducement Plan. Nektar's 2025 Inducement Plan was adopted by its Board of Directors on November 6, 2025 and is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of

    3/6/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Xunlei Limited Announces Entry into Definitive Agreements for Disposition of Majority Equity Interest in Shenzhen Onething

    SHENZHEN, China, March 03, 2026 (GLOBE NEWSWIRE) -- Xunlei Limited ("Xunlei" or the "Company") (NASDAQ:XNET), a leading technology company providing distributed cloud services in China, today announced that its variable interest entity in China, Shenzhen Xunlei Networking Technologies Co., Ltd. ("Shenzhen Xunlei"), has entered into definitive agreements to transfer an aggregate 50% equity interest in Shenzhen Onething Technology Co., Ltd. ("Shenzhen Onething") for an aggregate cash consideration of RMB125 million. Pursuant to the terms of the definitive agreements, Shenzhen Xunlei will transfer (i) 20% of the equity interest in Shenzhen Onething to Wuhan Kingsoft Cloud Information Technol

    3/3/26 8:00:00 AM ET
    $KC
    $XNET
    Computer Software: Prepackaged Software
    Technology

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $DB
    $KC
    $NKTR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Nektar Therapeutics

    SCHEDULE 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/6/26 10:05:20 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kingsoft Cloud Holdings Limited

    6-K - Kingsoft Cloud Holdings Ltd (0001795589) (Filer)

    3/5/26 6:21:27 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    SEC Form 6-K filed by Kingsoft Cloud Holdings Limited

    6-K - Kingsoft Cloud Holdings Ltd (0001795589) (Filer)

    3/3/26 9:11:00 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    $BNTX
    $DB
    $KC
    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief R&D Officer Zalevsky Jonathan sold $13,140 worth of shares (180 units at $73.00), decreasing direct ownership by 0.84% to 21,174 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:29 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Robin Howard W sold $30,879 worth of shares (423 units at $73.00), decreasing direct ownership by 0.56% to 75,489 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    2/20/26 7:10:10 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief R&D Officer Zalevsky Jonathan sold $137,936 worth of shares (3,867 units at $35.67), decreasing direct ownership by 15% to 21,354 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    1/22/26 7:31:42 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $DB
    $KC
    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Nektar Therapeutics upgraded by William Blair

    William Blair upgraded Nektar Therapeutics from Mkt Perform to Outperform

    2/10/26 11:48:14 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $DB
    $KC
    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    BioNTech to Host Innovation Series R&D Day on November 11, 2025

    MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 09:00 a.m. Eastern Standard Time (3:00 p.m. CET) on Tuesday, November 11, 2025 in New York City, U.S. On the day, members of BioNTech's leadership team will provide an overview of the Company's strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one year following the call. The public may also

    10/28/25 7:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $DB
    $KC
    $NKTR
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2025 on Thursday, March 12, 2026, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar web

    2/26/26 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

    MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the fourth quarter and full year 2025 on Tuesday, March 10, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will

    2/24/26 6:45:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing

    71% and 83% of patients maintained EASI-75 responses and 85% and 63% maintained vIGA-AD 0/1 responses with 24 µg/kg monthly and quarterly dosing, respectively Meaningful improvement in responses observed across key efficacy endpoints at week 52 with both monthly and quarterly dosing, including an up to 5-fold increase in EASI-100 response rates Favorable safety profile consistent with previously reported results for rezpegaldesleukin Durability of maintained response rates supports advancement to pivotal Phase 3 program evaluating both monthly and quarterly maintenance dosing Data validate novel first-in-class regulatory T-cell mechanism as a potential best-in-class immune-modulator Confere

    2/10/26 7:00:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $DB
    $KC
    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care